ARTL•benzinga•
EXCLUSIVE: Artelo Biosciences Tells Benzinga 'The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects', 'Initial safety and pharmacokinetic data expected during the first half 2025'
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2025 by benzinga